The Union Ministry of Health and Family Welfare said on January 12 that four more coronavirus vaccines are in the pipeline and may get the Drug Controller General of India (DGCI) nod for emergency use authorization soon.
The four other COVID-19 vaccines that are in the pipeline in India are:
Zydus Cadila’s coronavirus vaccine ZyCoV-D which has got the DGCI nod to conduct phase III trials in India.
Russia’s Sputnik V COVID-19 vaccine, which according to Dr Reddy’s Laboratories Ltd, meets the primary endpoint of safety in the phase II clinical trials in India.
Hyderabad-based Biological E (BE) completed the phase I trials of its protein subunit COVID-19 vaccine in December. Phase II trials will likely begin from March 2021.
Pune-based Genova Pharmaceuticals Ltd is working on India’s only messenger RNA based COVID-19 vaccine candidate. The phase I trial of the HGCO19 vaccine is on and the second phase of the trials are expected to begin from March 2021.
The health ministry then went to clarify that Hyderabad-based Bharat Biotech will be supplying 16.5 lakh doses of Covaxin free of cost to the government. The company will be charging the government only for the remaining 38.5 lakh doses at Rs 295 per dose. Considering the total procurement is of 55 lakh doses, the price of Bharat Biotech’s Covaxin comes down to Rs 206 per dose.
Additionally, the government has also signed a purchase order with SII for 119 lakh doses of Covishield at Rs 200 per dose.
Follow our coverage of the coronavirus crisis here
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
